本文選題：免疫性腎小球疾病 + 他克莫司　； 參考：《醫(yī)學與哲學(B)》2017年05期

【摘要】：對單用他克莫司和聯(lián)合五酯膠囊治療免疫性腎小球疾病療效、安全性和藥物-經(jīng)濟效益進行比較�；仡櫺苑治龃筮B醫(yī)科大學附屬第一醫(yī)院2011年1月~2015年12月行腎活檢證實為免疫性腎小球疾病并伴大量蛋白尿的患者60例,分為單用他克莫司組和聯(lián)合五酯膠囊組。主要評價指標:蛋白尿緩解率、各個時間點蛋白尿緩解率等;次要評價指標:藥物副作用、治療費用及藥物-經(jīng)濟學效益。隨訪第3個月、6個月,他克莫司聯(lián)合五酯膠囊組蛋白尿緩解人數(shù)高于單用他克莫司組(P0.05),兩組副作用無差異(P0.05),而治療費用及成本-療效比有統(tǒng)計學差異(P0.05);他克莫司聯(lián)合五酯膠囊可有效降低免疫性腎小球疾病蛋白尿,且具有較好藥物經(jīng)濟學效益。
[Abstract]:The efficacy, safety and pharmaco-economic benefit of tacrolimus and pentyl ester capsules in the treatment of immune glomerular diseases were compared. From January 2011 to December 2015, 60 patients with immunologic glomerular disease and large proteinuria were analyzed retrospectively. They were divided into two groups: tacrolimus group and combined pentyl ester capsule group. Main outcome measures: remission rate of proteinuria, remission rate of proteinuria at different time points, secondary evaluation measures: side effects of drugs, treatment costs and pharmaco-economic benefits. They were followed up for 3 months, 6 months, The remission of proteinuria in tacrolimus combined with pentyl ester capsule group was higher than that in tacrolimus group alone, and there was no difference in side effects between the two groups (P 0.05), while there was significant difference in the cost of treatment and the ratio of cost to curative effect (P 0.05), and tacrolimus combined with pentyl ester capsule was effective in reducing the incidence of proteinuria. Low immune glomerular disease proteinuria, And has good pharmacoeconomics benefit.
【作者單位】： 大連醫(yī)科大學附屬第一醫(yī)院腎內科;
【分類號】：R692.6

【相似文獻】

相關期刊論文 前2條

1 唐薇;胡丹;楊荊艷;;腎移植受者聯(lián)合應用五酯膠囊與FK506的藥物經(jīng)濟學研究[J];護理實踐與研究;2011年04期

2 ;[J];;年期

相關會議論文 前1條

1 陳剛;朱蘭;張紅;黃偉;汪芯;李娟;林正斌;;五酯膠囊在臨床腎移植受者的實際應用中對他克莫司藥代動力學的影響及與CYP3A5基因型的相關性分析[A];2012中國器官移植大會論文匯編[C];2012年

相關博士學位論文 前1條

1 王筱嘯;臨床腎移植若干重要問題探討[D];華中科技大學;2014年

相關碩士學位論文 前1條

1 劉順芳;他克莫司單用和聯(lián)合五酯膠囊治療免疫性腎小球疾病的單中心回顧性研究[D];大連醫(yī)科大學;2016年

，

本文編號：1857698